Page 2114 - Williams Hematology ( PDFDrive )

2088 Part XII: Hemostasis and Thrombosis Chapter 121: Acquired Qualitative Platelet Disorders 2089

134. Burroughs SF, Johnson GJ: Beta-lactam antibiotic-induced platelet dysfunction: Evi- 168. Barnathan ES, Addonizio VP, Shattil SJ: Interaction of verapamil with human platelet
dence for irreversible inhibition of platelet activation in vitro and in vivo after pro- alpha-adrenergic receptors. Am J Physiol 242(1):H19–H23, 1982.
longed exposure to penicillin. Blood 75(7):1473–1480, 1990. 169. Fujinishi A, Takahara K, Ohba C, et al: Effects of nisoldipine on cytosolic calcium,
135. Sattler FR, Weitekamp MR, Sayegh A, Ballard JO: Impaired hemostasis caused by beta- platelet aggregation, and coagulation/fibrinolysis in patients with coronary artery dis-
lactam antibiotics. Am J Surg 155(5A):30–39, 1988. ease. Angiology 48(6):515–521, 1997.
136. Giles AR, Greenwood P, Tinlin S: A platelet release defect induced by aspirin or peni- 170. Lawson D, Mehta J, Mehta P, et al: Cumulative effects of quinidine and aspirin on bleed-
cillin G does not increase gastrointestinal blood loss in thrombocytopenic rabbits. Br J ing time and platelet a -adrenoceptors: Potential mechanism of bleeding diathesis in
2
Haematol 57(1):17–23, 1984. patients receiving this combination. J Lab Clin Med 108:581, 1986.
137. Andrassy K, Koderisch J, Trenk D, et al: Hemostasis in patients with normal and impaired 171. Aberg M, Hedner U, Bergentz SE: Effect of dextran 70 on factor VIII and platelet func-
renal function under treatment with cefodizime. Infection 15(5):348–350, 1987. tion in von Willebrand’s disease. Thromb Res 12(4):629–634, 1978.
138. Bloom A, Greaves M, Preston FE, Brown CB: Evidence against a platelet cyclooxygen- 172. Mishler JM 4th: Synthetic plasma volume expanders—Their pharmacology, safety and
ase defect in uraemic subjects on chronic haemodialysis. Br J Haematol 62:143, 1986. clinical efficacy. Clin Haematol 13(1):75–92, 1984.
139. Rossi EC, Levin NW: Inhibition of primary ADP-induced platelet aggregation in 173. Kelton JG, Hirsh J: Bleeding associated with antithrombotic therapy. Semin Hematol
normal subjects after administration of nitrofurantoin (furadantin). J Clin Invest 17(4):259–291, 1980.
52(10):2457–2467, 1973. 174. Korttila K, Lauritsalo K, Sarmo A, et al: Suitability of plasma expanders in patients
140. Ishikawa S, Manabe S, Wada O: Miconazole inhibition of platelet aggregation by inhib- receiving low-dose heparin for prevention of venous thrombosis after surgery. Acta
iting cyclooxygenase. Biochem Pharmacol 35(11):1787–1792, 1986. Anaesthesiol Scand 27(2):104–107, 1983.
141. Salzman EW, Rosenberg RD, Smith MH, et al: Effect of heparin and heparin fractions 175. Cope JT, Banks D, Mauney MC, et al: Intraoperative hetastarch infusion impairs hemo-
on platelet aggregation. J Clin Invest 65(1):64–73, 1980. stasis after cardiac operations. Ann Thorac Surg 63(1):78–82; discussion 82–83, 1997.
142. Horne MK 3rd, Chao ES: Heparin binding to resting and activated platelets. Blood 176. Ruttmann TG, James MF, Aronson I: In vivo investigation into the effects of haemodilu-
74(1):238–243, 1989. tion with hydroxyethyl starch (200/0.5) and normal saline on coagulation. Br J Anaesth
143. Sobel M, McNeill PM, Carlson PL, et al: Heparin inhibition of von Willebrand factor- 80(5):612–616, 1998.
dependent platelet function in vitro and in vivo. J Clin Invest 87(5):1787–1793, 1991. 177. Roberts JS, Bratton SL: Colloid volume expanders. Problems, pitfalls and possibilities.
144. Coller BS: Platelets and thrombolytic therapy. N Engl J Med 322(1):33–42, 1990. Drugs 55(5):621–630, 1998.
145. Niewiarowski S, Senyi AF, Gillies P: Plasmin-induced platelet aggregation and platelet 178. Avorn J, Patel M, Levin R, Winkelmayer WC: Hetastarch and bleeding complications
release reaction. Effects on hemostasis. J Clin Invest 52(7):1647–1659, 1973. after coronary artery surgery. Chest 124(4):1437–1442, 2003.
146. Fitzgerald DJ, Catella F, Roy L, FitzGerald GA: Marked platelet activation in vivo after 179. Treib J, Haass A, Pindur G: Coagulation disorders caused by hydroxyethyl starch.
intravenous streptokinase in patients with acute myocardial infarction. Circulation Thromb Haemost 78(3):974–983, 1997.
77(1):142–150, 1988. 180. Scharbert G, Deusch E, Kress HG, et al: Inhibition of platelet function by hydroxyethyl
147. Kerins DM, Roy L, FitzGerald GA, Fitzgerald DJ: Platelet and vascular function during starch solutions in chronic pain patients undergoing peridural anesthesia. Anesth Analg
coronary thrombolysis with tissue-type plasminogen activator. Circulation 80(6):1718– 99(3):823–827, 2004.
1725, 1989. 181. Svehla C, Spankova H, Mlejnkova M: The effect of tricyclic antidepressive drugs on
148. Thorsen LI, Brosstad F, Gogstad G, et al: Competitions between fibrinogen with its adrenaline and adenosine diphosphate induced platelet aggregation. J Pharm Pharma-
degradation products for interactions with the platelet-fibrinogen receptor. Thromb Res col 18(9):616–617, 1966.
44(5):611–623, 1986. 182. Warlow C, Ogston D, Douglas AS: Platelet function after the administration of chlor-
149. Miles LA, Ginsberg MH, White JG, Plow EF: Plasminogen interacts with human plate- promazine to human subjects. Haemostasis 5(1):21–26, 1976.
lets through two distinct mechanisms. J Clin Invest 77(6):2001–2009, 1986. 183. Morishita S, Aoki S, Watanabe S: Different effect of desipramine on protein kinase C
150. Adelman B, Michelson AD, Loscalzo J, et al: Plasmin effect on platelet glycoprotein in platelets between bipolar and major depressive disorders. Psychiatry Clin Neurosci
Ib-von Willebrand factor interactions. Blood 65(1):32–40, 1985. 53(1):11–15, 1999.
151. Stricker RB, Wong D, Shiu DT, et al: Activation of plasminogen by tissue plasminogen 184. Hergovich N, Aigner M, Eichler HG, et al: Paroxetine decreases platelet serotonin stor-
activator on normal and thrombasthenic platelets: Effects on surface proteins and plate- age and platelet function in human beings. Clin Pharmacol Ther 68(4):435–442, 2000.
let aggregation. Blood 68(1):275–280, 1986. 185. Alderman CP, Seshadri P, Ben-Tovim DI: Effects of serotonin reuptake inhibitors on
152. Schafer AI, Adelman B: Plasmin inhibition of platelet function and of arachidonic acid hemostasis. Ann Pharmacother 30(11):1232–1234, 1996.
metabolism. J Clin Invest 75(2):456–461, 1985. 186. Pai VB, Kelly MW: Bruising associated with the use of fluoxetine. Ann Pharmacother
153. Loscalzo J, Vaughan DE: Tissue plasminogen activator promotes platelet disaggregation 30(7–8):786–788, 1996.
in plasma. J Clin Invest 79(6):1749–1755, 1987. 187. Corbin F, Blaise G, Sauve R: Differential effect of halothane and forskolin on platelet
154. Penny WF, Ware JA: Platelet activation and subsequent inhibition by plasmin and cytosolic Ca2+ mobilization and aggregation. Anesthesiology 89(2):401–410, 1998.
recombinant tissue-type plasminogen activator. Blood 79(1):91–98, 1992. 188. Aoki H, Mizobe T, Nozuchi S, Hiramatsu N: In vivo and in vitro studies of the inhibitory
155. Winters KJ, Eisenberg PR, Jaffe AS, Santoro SA: Dependence of plasmin-mediated deg- effect of propofol on human platelet aggregation. Anesthesiology 88(2):362–370, 1998.
radation of platelet adhesive receptors on temperature and Ca2+. Blood 76(8):1546– 189. Heesch CM, Negus BH, Steiner M, Set al: Effects of in vivo cocaine administration on
1557, 1990. human platelet aggregation. Am J Cardiol 78(2):237–239, 1996.
156. Hines R, Barash PG: Infusion of sodium nitroprusside induces platelet dysfunction in 190. Jennings LK, White MM, Sauer CM, et al: Cocaine-induced platelet defects. Stroke
vitro. Anesthesiology 70(4):611–615, 1989. 24(9):1352–1359, 1993.
157. Kroll MH, Schafer AI: Biochemical mechanisms of platelet activation. Blood 74:1181– 191. Togna G, Graziani M, Sorrentino C, Caprino L: Prostanoid production in the presence
1195, 1989. of platelet activation in hypoxic cocaine-treated rats. Haemostasis 26(6):311–318, 1996.
158. Anfossi G, Russo I, Massucco P, et al: Studies on inhibition of human platelet func- 192. Batista A, Macedo T, Tavares P, et al: Nitric oxide production and nitric oxide synthase
tion by sodium nitroprusside. Kinetic evaluation of the effect on aggregation and cyclic expression in platelets from heroin abusers before and after ultrarapid detoxification.
nucleotide content. Thromb Res 102(4):319–330, 2001. Ann N Y Acad Sci 965:479–486, 2002.
159. Bozzo J, Hernandez MR, Galan AM, et al: Antiplatelet effects of sodium nitroprusside 193. Ahr DJ, Scialla SJ, Kimbali DB Jr: Acquired platelet dysfunction following mithramycin
in flowing human blood: Studies under normoxic and hypoxic conditions. Thromb Res therapy. Cancer 41(2):448–454, 1978.
97(4):217–225, 2000. 194. Panella TJ, Peters W, White JG, et al: Platelets acquire a secretion defect after high-dose
160. Jang EK, Azzam JE, Dickinson NT, et al: Roles for both cyclic GMP and cyclic AMP in chemotherapy. Cancer 65(8):1711–1716, 1990.
the inhibition of collagen-induced platelet aggregation by nitroprusside. Br J Haematol 195. Pogliani EM, Fantasia R, Lambertenghi-Deliliers G, Cofrancesco E: Daunorubicin and
117(3):664–675, 2002. platelet function. Thromb Haemost 45(1):38–42, 1981.
161. Schafer AI, Alexander RW, Handin RI: Inhibition of platelet function by organic nitrate 196. McKenna R, Ahmad T, Ts’ao CH, Frischer H: Glutathione reductase deficiency and
vasodilators. Blood 55(4):649–654, 1980. platelet dysfunction induced by 1,3-bis(2-chloroethyl)-1-nitrosourea. J Lab Clin Med
162. Weksler BB, Gillick M, Pink J: Effect of propranolol on platelet function. Blood 102(1):102–115, 1983.
49(2):185–196, 1977. 197. Karolak L, Chandra A, Khan W, et al: High-dose chemotherapy-induced platelet
163. Leon R, Tiarks CY, Pechet L: Some observations on the in vivo effect of propranolol on defect: Inhibition of platelet signal transduction pathways. Mol Pharmacol 43(1):37–44,
platelet aggregation and release. Am J Hematol 5(2):117–121, 1978. 1993.
164. Hines R: Preservation of platelet function during trimethaphan infusion. Anesthesiol- 198. O’Malley CJ, Rasko JE, Basser RL, et al: Administration of pegylated recombinant
ogy 72(5):834–837, 1990. human megakaryocyte growth and development factor to humans stimulates the
165. Hogman M, Frostell C, Arnberg H, Hedenstierna G: Bleeding time prolongation and production of functional platelets that show no evidence of in vivo activation. Blood
NO inhalation. Lancet 341(8861):1664–1665, 1993. 88(9):3288–3298, 1996.
166. Samama CM, Diaby M, Fellahi JL, et al: Inhibition of platelet aggregation by inhaled 199. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al: Stimulation of megakaryocyte and
nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology platelet production by a single dose of recombinant human thrombopoietin in patients
83(1):56–65, 1995. with cancer. Ann Intern Med 126(9):673–681, 1997.
167. Gries A, Bode C, Peter K, et al: Inhaled nitric oxide inhibits human platelet aggre- 200. Gratacap MP, Martin V, Valera MC, et al: The new tyrosine-kinase inhibitor and anti-
gation, P-selectin expression, and fibrinogen binding in vitro and in vivo. Circulation cancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood
97(15):1481–1487, 1998. 114(9):1884–1892, 2009.

Kaushansky_chapter 121_p2073-2096.indd 2089 9/18/15 10:28 AM